Glossary
NMN
Nicotinamide mononucleotide sits one step before NAD+: NAMPT makes it, NMNAT converts it. Chemistry, the cellular uptake debate and how it is studied.
NMN (nicotinamide mononucleotide) is the immediate precursor of NAD+ in the salvage route that mammalian cells use. NAMPT combines nicotinamide with PRPP to form NMN, which NMNAT enzymes then adenylylate to NAD+ in a single additional step. NAMPT is the slowest, rate-limiting enzyme of the route, so providing NMN beyond that bottleneck is the rationale for using it in metabolic experiments.
NMN in the research literature
Rodent studies published from roughly 2011 reported higher NAD+ in tissues together with changes in insulin sensitivity and in mitochondrial and vascular measures after NMN was given; a small number of clinical studies since 2020 describe biomarker shifts alongside modest, inconsistent functional results. One mechanistic question remains open — transport. As a charged, phosphate-bearing molecule, NMN may first be converted to nicotinamide riboside outside the cell and only then taken up, while other studies point to a dedicated transporter (Slc12a8). Because of that disagreement, researchers frequently compare NAD+, NR and NMN in parallel instead of being treated as equivalent.
Regulatory note: since 2022 US authorities and industry have disputed whether NMN may be sold in dietary supplements, which is one of the reasons it is offered here purely as research-grade material.
Related terms and material
See also AMPK, sirtuins and the note on FDA-approved vs research-grade material. In the shop: NMN and the vitamin & cofactor range; our explainers compare NAD+ with NMN and introduce NMN itself.